CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

(2015) Daniel Weintraub et al.   MOVEMENT DISORDERS

CSF A 42 predicts early-onset dementia in Parkinson disease

(2014) G. Alves et al.   NEUROLOGY

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

(2014) Lucilla Parnetti et al.   Frontiers in Aging Neuroscience

Cerebrospinal fluid biomarkers in Parkinson disease

(2013) Lucilla Parnetti et al.   Nature Reviews Neurology

Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study

(2013) Yaroslau Compta et al.   PARKINSONISM & RELATED DISORDERS

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

(2012) Irene Litvan et al.   MOVEMENT DISORDERS

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

(2011) Leslie M. Shaw et al.   ACTA NEUROPATHOLOGICA

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

CSF amyloid-  and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

(2010) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CSF Aβ42and tau in Parkinson's disease with cognitive impairment

(2010) Thomas J. Montine et al.   MOVEMENT DISORDERS

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

(2009) M. A. Burack et al.   NEUROLOGY